Tumor size changes in melanoma patients (Ipilimumab-Naive melanoma (KEYNOTE-006))
| Number of Line of Therapy | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1L | 2L | |||||||
| n | Median | Mean | Standard Deviation | n | Median | Mean | Standard Deviation | |
| Pembrolizumab arm | ||||||||
| % of Early Tumor Sizes Changes (~Week 12) | 282 | −24.2 | −19.7 | 42.5 | 152 | −9.1 | −9.0 | 47.2 |
| Best % of Tumor Size Changes | 282 | −53.0 | −40.8 | 52.4 | 152 | −36.3 | −29.1 | 57.8 |
| Ipilimumab arm | ||||||||
| % of Early Tumor Size Changes (~ Week 12) | 124 | 7.8 | 6.6 | 46.0 | 61 | −1.6 | 5.3 | 62.1 |
| Best % of Tumor Size Changes | 124 | −6.5 | −7.0 | 56.2 | 61 | −9.7 | −6.8 | 70.2 |